6 citations
,
January 2019 in “Journal of dermatology” Immune checkpoint inhibitors used in cancer therapy can cause hair loss, and understanding this can help manage the side effect.
25 citations
,
October 2019 in “JAAD Case Reports” Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.
September 2025 in “Journal of Skin and Stem Cell” Baricitinib shows promise for treating various skin conditions beyond alopecia areata.
5 citations
,
September 2022 in “Journal of Investigative Dermatology” Careful selection of mice by genetics and age, and controlled housing conditions improve the reliability of hair regrowth in wound healing tests.
November 2025 in “Skin Appendage Disorders” Immune cell-targeting biologics show potential for treating alopecia areata but need better-targeted therapies.
1 citations
,
August 2023 in “Journal of Investigative Dermatology” Farudodstat may help treat alopecia areata by protecting hair follicles.
April 2023 in “Journal of Investigative Dermatology” A new pain-measuring system using sensors and AI can effectively detect pain in mice, which may help assess pain in humans and develop treatments.
12 citations
,
October 2024 in “Expert Opinion on Drug Discovery” New, effective treatments for alopecia areata require innovative approaches targeting the immune system.
Vegan exosome-like vesicles from microalgae improve skin and hair health, reducing wrinkles and enhancing elasticity.
1 citations
,
June 2023 in “American Journal of Clinical Dermatology” Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.
December 2011 in “Asia-Pacific biotech news” In 2011, there were major scientific breakthroughs in cancer treatment, immunity, Parkinson's, virus simulation, schizophrenia, hair growth, lung cancer, and medical grafts.
1 citations
,
March 2023 in “Portuguese Journal of Dermatology and Venereology” Cannabis might help hair regrowth in alopecia areata.
April 2023 in “Journal of Investigative Dermatology” The research developed methods to test drugs that could protect and restore hair follicle protection in a hair loss condition.
Patients and doctors often agree on the severity of eyebrow and eyelash hair loss in severe alopecia areata.
September 2023 in “Drugs in context” Baricitinib is a promising treatment for alopecia areata.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Upadacitinib effectively treats severe alopecia areata and is safe.
July 2025 in “Journal of Investigative Dermatology” AI-09 is safe, effective, and reduces wrinkles for up to 6 months.
4 citations
,
January 2020 in “PubMed” JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
March 2014 in “Journal of The American Academy of Dermatology” A botanical extract may help manage hair loss from chemotherapy by preventing cell death in hair follicles.
November 2025 in “Reumatismo” The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.
May 2025 in “Experimental Dermatology” A new genetic tool improves the study of hair growth and potential hair disorder treatments.
56 citations
,
January 2019 in “Lancet” JAK inhibitors help regrow hair in alopecia areata patients, improving their quality of life.
April 2025 in “PharmacoEconomics - Open” Patients with Alopecia Areata are willing to trade life duration for better quality of life.
June 2025 in “British Journal of Dermatology” JAK inhibitors help regrow hair in alopecia areata, but their long-term safety is still unclear.
February 2026 in “Biomaterials” BOOST is a promising, easy-to-use treatment for diabetic foot ulcers that improves healing by reducing inflammation and promoting blood vessel growth.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
14 citations
,
March 2022 in “Journal of inflammation research” Baricitinib shows promise as a new treatment for certain skin conditions like alopecia areata.
July 2008 in “Journal of Intellectual Property Law & Practice” The UK Court of Appeal ruled that new dosing regimens for drugs can be patented, aligning with the European Patent Office's approach.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” SM04554 may increase hair growth as a topical treatment for androgenetic alopecia.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Baricitinib is widely used for several conditions, especially COVID-19, but its safety and effectiveness are still being evaluated.